• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新诊断膀胱癌患者以下尿路症状为首发表现的发生率及临床特点。

Incidence and clinical characteristics of lower urinary tract symptoms as a presenting symptom for patients with newly diagnosed bladder cancer.

机构信息

Department of Urology, Atlanta Veterans Affairs Medical Center and Emory University School of Medicine, Atlanta, Georgia, USA.

出版信息

Int Braz J Urol. 2014 Mar-Apr;40(2):198-203. doi: 10.1590/S1677-5538.IBJU.2014.02.09.

DOI:10.1590/S1677-5538.IBJU.2014.02.09
PMID:24856486
Abstract

PURPOSE

The incidence of lower urinary tract symptoms (LUTS) as the sole presenting symptom for bladder cancer has traditionally been reported to be low. The objective of this study was to evaluate the prevalence and clinical characteristics of newly diagnosed bladder cancer patients who presented with LUTS in the absence of gross or microscopic hematuria.

MATERIALS AND METHODS

We queried our database of bladder cancer patients at the Atlanta Veteran's Affairs Medical Center (AVAMC) to identify patients who presented solely with LUTS and were subsequently diagnosed with bladder cancer. Demographic, clinical, and pathologic variables were examined.

RESULTS

4.1% (14/340) of bladder cancer patients in our series presented solely with LUTS. Mean age and Charlson Co-morbidity Index of these patients was 66.4 years (range = 52-83) and 3 (range = 0-7), respectively. Of the 14 patients in our cohort presenting with LUTS, 9 (64.3%), 4 (28.6%), and 1 (7.1%) patients presented with clinical stage Ta, carcinoma in Situ (CIS), and T2 disease. At a median follow-up of 3.79 years, recurrence occurred in 7 (50.0%) patients with progression occurring in 1 (7.1%) patient. 11 (78.6%) patients were alive and currently disease free, and 3 (21.4%) patients had died, with only one (7.1%) death attributable to bladder cancer.

CONCLUSIONS

Our database shows a 4.1% incidence of LUTS as the sole presenting symptom in patients with newly diagnosed bladder cancer. This study suggests that urologists should have a low threshold for evaluating patients with unexplained LUTS for underlying bladder cancer.

摘要

目的

下尿路症状(LUTS)作为膀胱癌唯一的首发症状,其发病率传统上一直被认为较低。本研究旨在评估以 LUTS 为首发症状而无肉眼或镜下血尿的初诊膀胱癌患者的患病率和临床特征。

材料和方法

我们在亚特兰大退伍军人事务医疗中心(AVAMC)的膀胱癌患者数据库中查询,以确定仅表现为 LUTS 并随后被诊断为膀胱癌的患者。检查了人口统计学、临床和病理变量。

结果

在我们的研究系列中,有 4.1%(14/340)的膀胱癌患者仅表现为 LUTS。这些患者的平均年龄和 Charlson 合并症指数分别为 66.4 岁(范围为 52-83)和 3(范围为 0-7)。在我们的 LUTS 首发患者队列中,有 9 名(64.3%)、4 名(28.6%)和 1 名(7.1%)患者分别表现为临床 Ta 期、原位癌(CIS)和 T2 期疾病。在中位随访 3.79 年时,7 名(50.0%)患者出现复发,1 名(7.1%)患者出现进展。11 名(78.6%)患者存活且目前无疾病,3 名(21.4%)患者死亡,仅 1 名(7.1%)死亡归因于膀胱癌。

结论

我们的数据库显示,新发膀胱癌患者以 LUTS 为唯一首发症状的发病率为 4.1%。本研究表明,泌尿科医生应该对不明原因的 LUTS 患者进行膀胱癌的评估,阈值应较低。

相似文献

1
Incidence and clinical characteristics of lower urinary tract symptoms as a presenting symptom for patients with newly diagnosed bladder cancer.新诊断膀胱癌患者以下尿路症状为首发表现的发生率及临床特点。
Int Braz J Urol. 2014 Mar-Apr;40(2):198-203. doi: 10.1590/S1677-5538.IBJU.2014.02.09.
2
Re-examination of the natural history of high-grade T1 bladder cancer using a large contemporary cohort.使用大型当代队列重新检查高级 T1 膀胱癌的自然病史。
Int Braz J Urol. 2014 Mar-Apr;40(2):172-8. doi: 10.1590/S1677-5538.IBJU.2014.02.06.
3
Superficial bladder tumours: recurrence and progression.浅表性膀胱肿瘤:复发与进展
J Coll Physicians Surg Pak. 2011 Mar;21(3):157-60.
4
Assessment of lower urinary tract symptoms in men by international prostate symptom score and core lower urinary tract symptom score.国际前列腺症状评分和核心下尿路症状评分评估男性下尿路症状。
BJU Int. 2012 May;109(10):1512-6. doi: 10.1111/j.1464-410X.2011.10445.x. Epub 2011 Aug 26.
5
Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.女性性别和前列腺尿道原位癌是 T1G3 膀胱癌患者接受卡介苗治疗后复发、进展和疾病特异性死亡率的预后因素。
Eur Urol. 2012 Jul;62(1):118-25. doi: 10.1016/j.eururo.2011.10.029. Epub 2011 Oct 25.
6
Analysis of factors predicting intravesical recurrence of superficial transitional cell carcinoma of the bladder without concomitant carcinoma in situ.无原位癌伴发的膀胱浅表性移行细胞癌膀胱内复发预测因素分析
Int J Urol. 2006 Nov;13(11):1389-92. doi: 10.1111/j.1442-2042.2006.01562.x.
7
Upper urinary tract recurrence following radical cystectomy for bladder cancer: a meta-analysis on 13,185 patients.膀胱癌根治性膀胱切除术后上尿路复发:13185 例患者的荟萃分析。
J Urol. 2012 Dec;188(6):2046-54. doi: 10.1016/j.juro.2012.08.017. Epub 2012 Oct 18.
8
Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.根据日本登记膀胱癌患者的数据得出的Ta、T1期非肌层浸润性膀胱癌肿瘤复发的临床结果:日本泌尿外科学会1999 - 2001年报告
Int J Urol. 2009 Mar;16(3):279-86. doi: 10.1111/j.1442-2042.2008.02235.x. Epub 2009 Jan 20.
9
Lower Urinary Tract Symptoms and Risk of Bladder Cancer in Men: Results From the Health Professionals Follow-up Study.男性下尿路症状与膀胱癌风险:健康专业人员随访研究结果
Urology. 2015 Jun;85(6):1312-8. doi: 10.1016/j.urology.2015.02.024. Epub 2015 Apr 8.
10
Moderate or severe LUTS is associated with increased recurrence of non - muscle - invasive urothelial carcinoma of the bladder.中重度下尿路症状与非肌层浸润性膀胱尿路上皮癌的复发相关。
Int Braz J Urol. 2019 Mar-Apr;45(2):306-314. doi: 10.1590/S1677-5538.IBJU.2018.0068.

引用本文的文献

1
The importance of multimodal diagnostic methods for therapeutic decision making for overactive bladder in women.多模态诊断方法对女性膀胱过度活动症治疗决策的重要性。
Med Pharm Rep. 2025 Apr;98(2):165-175. doi: 10.15386/mpr-2669. Epub 2025 Apr 29.
2
Humanistic and Economic Burden of Non-Muscle Invasive Bladder Cancer: Results of Two Systematic Literature Reviews.非肌层浸润性膀胱癌的人文及经济负担:两项系统文献综述的结果
Clinicoecon Outcomes Res. 2020 Nov 23;12:693-709. doi: 10.2147/CEOR.S274951. eCollection 2020.
3
Complete reversal of the clinical symptoms and image morphology of ketamine cystitis after intravesical hyaluronic acid instillation: A case report.
膀胱内注射透明质酸后氯胺酮膀胱炎临床症状及影像形态完全逆转:一例报告
Medicine (Baltimore). 2018 Jul;97(28):e11500. doi: 10.1097/MD.0000000000011500.
4
Development and Validation of the Korean Version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients with Non-muscle Invasive Bladder Cancer: EORTC QLQ-NMIBC24.欧洲癌症研究与治疗组织膀胱癌患者生活质量问卷非肌肉浸润性膀胱癌模块 24 中文版的制定与验证
Cancer Res Treat. 2018 Jan;50(1):40-49. doi: 10.4143/crt.2016.594. Epub 2017 Mar 10.
5
Early Stage Bladder Cancer: Do Pathology Reports Tell Us What We Need to Know?早期膀胱癌:病理报告能告诉我们所需了解的信息吗?
Urology. 2016 Dec;98:58-63. doi: 10.1016/j.urology.2016.07.040. Epub 2016 Aug 30.
6
Neutrophil to lymphocyte ratio, a biomarker in non-muscle invasive bladder cancer: a single-institutional longitudinal study.中性粒细胞与淋巴细胞比值,一种非肌层浸润性膀胱癌的生物标志物:一项单机构纵向研究。
Int Braz J Urol. 2016 Jul-Aug;42(4):685-93. doi: 10.1590/S1677-5538.IBJU.2015.0243.
7
Overactive bladder - 18 years - Part I.膀胱过度活动症 - 18岁 - 第一部分。
Int Braz J Urol. 2016 Mar-Apr;42(2):188-98. doi: 10.1590/S1677-5538.IBJU.2015.0365.